A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV

AIDS and Behavior

Volumn 19, Issue , 2015, Pages 156-162

  Moore, Brent A ^a,f   Rosen, Marc I ^a,f   Wang, Yan ^b   Shen, Jie ^c   Ablondi, Karen ^a,f   Sullivan, Anna ^a,f   Guerrero, Mario ^d   Siqueiros, Lisa ^d   Daar, Eric S ^d,e   Liu, Honghu ^b,c,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Adherence; AIDS; Compliance; Contingency management; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; COGNITIVE THERAPY; COMPLICATION; DIRECTIVE COUNSELING; FEASIBILITY STUDY; FEMALE; HIV INFECTIONS; HUMAN; MALE; MEDICATION COMPLIANCE; MOTIVATION; PATIENT ATTITUDE; PROCEDURES; PROGRAM EVALUATION; PSYCHOLOGY; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS; TELEPHONE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADULT; ANTI-RETROVIRAL AGENTS; CALIFORNIA; COGNITIVE THERAPY; DIRECTIVE COUNSELING; FEASIBILITY STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MOTIVATION; PATIENT ACCEPTANCE OF HEALTH CARE; PROGRAM EVALUATION; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; TELEPHONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937632489     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-014-0990-x     Document Type: Article

References (45)

1. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41(2):194–200.
2. Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, et al. AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. Aids. 2010;24(10):1549–59.
3. Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C. Ocular Complications of ARG. Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis. 2010;51(8):947–56.
4. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.
5. Bangsberg DR. Less than 95 % adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.
6. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65–72.
7. Shuper PA, Neuman M, Kanteres F, Baliunas D, Joharchi N, Rehm J. Causal considerations on alcohol and HIV/AIDS–a systematic review. Alcohol Alcohol. 2010;45(2):159–66.
8. Aloisi MS, Arici C, Balzano R, Noto P, Piscopo R, Filice G, et al. Behavioral correlates of adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S145–8.
9. Ortego C, Huedo-Medina T, Llorca J, Sevilla L, Santos P, Rodríguez E, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381–1396.
10. Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, Simoni JM, et al. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav. 2013;17(1):142–7.
11. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retrovir. 2010;26(5):511–8.
12. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. JAIDS J Acquir Immune Defic Syndr. 2009;50(1):93–9. doi:10.1097/QAI.0b013e3181900129.
13. Cook JA, Burke-Miller JK, Cohen MH, Cook RL, Vlahov D, Wilson TE, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS. 2008;22(11):1355–63 (London, England).
14. Sullivan LE, Botsko M, Cunningham CO, O’Connor PG, Hersh D, Mitty J, et al. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. JAIDS J Acquir Immune Defic Syndr. 2011;56:S54–61. doi:10.1097/QAI.0b013e3182097576.
15. Cofrancesco J Jr, Scherzer R, Tien PC, Gibert CL, Southwell H, Sidney S, et al. Illicit drug use and HIV treatment outcomes in a US cohort. Aids. 2008;22(3):357–65.
16. Hicks PL, Mulvey KP, Chander G, Fleishman JA, Josephs JS, Korthuis PT, et al. The impact of illicit drug use and substance abuse treatment on adherence to HAART. AIDS Care. 2007;19(9):1134–40.
17. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008. doi:10.1002/14651858.CD000011.pub3.
18. Rigsby MO, Rosen MI, Beauvais JE, Cramer JA, Rainey PM, O’Malley SS, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000;15(12):841–7.
19. Rosen MI, Dieckhaus K, McMahon TJ, Valdes B, Petry NM, Cramer J, et al. Improved adherence with contingency management. AIDS Patient Care STDS. 2007;21(1):30–40.
20. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007;88(1):54–63.
21. Dallery J, Raiff BR, Grabinski MJ. Internet-based contingency management to promote smoking cessation: a randomized controlled study. J Appl Behav Anal. 2013;46(4):750–64.
22. Dallery J, Glenn IM, Raiff BR. An Internet-based abstinence reinforcement treatment for cigarette smoking. Drug Alcohol Depend. 2007;86(2–3):230–8.
23. Stoops WW, Dallery J, Fields NM, Nuzzo PA, Schoenberg NE, Martin CA, et al. An internet-based abstinence reinforcement smoking cessation intervention in rural smokers. Drug Alcohol Depend. 2009;105(1–2):56–62.
24. Alessi SM, Petry NM. A randomized study of cellphone technology to reinforce alcohol abstinence in the natural environment. Addiction. 2013;108(5):900–9 (Abingdon, England).
25. Raiff BR, Dallery J. Internet-based contingency management to improve adherence with blood glucose testing recommendations for teens with type 1 diabetes. J Appl Behav Anal. 2010;43(3):487–91.
26. Ferster CB, Skinner BF. Schedules of reinforcement. New York: Appleton-Century-Crofts; 1957.
27. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006;26(1):17–31.
28. McHugh RK, Hearon BA, Otto MW. Cognitive behavioral therapy for substance use disorders. Psychiatr Clin N Am. 2010;33(3):511–25.
29. Muller I, Yardley L. Telephone-delivered cognitive behavioural therapy: a systematic review and meta-analysis. J Telemed Telecare. 2011;17(4):177–84.
30. Mohr DC, Ho J, Duffecy J, Reifler D, Sokol L, Burns MN, et al. Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial. JAMA. 2012;307(21):2278–85.
31. Himelhoch S, Medoff D, Maxfield J, Dihmes S, Dixon L, Robinson C, et al. Telephone based cognitive behavioral therapy targeting major depression among urban dwelling, low income people living with HIV/AIDS: results of a randomized controlled trial. AIDS Behav. 2013;17(8):2756–64.
32. Collier AC, Ribaudo H, Mukherjee AL, Feinberg J, Fischl MA, Chesney M. A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. J Infect Dis. 2005;192(8):1398–406.
33. Carroll KM. A cognitive-behavioral approach: treating cocaine addiction. Rockville: NIDA; 1998.
34. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.
35. Rosen MI, Ryan C, Rigsby M. Motivational Enhancement and MEMS review to improve medication adherence. Behav Chang. 2002;19:183–90.
36. Wagner GJ, Kanouse DE, Golinelli D, Miller LG, Daar ES, Witt MD, et al. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). Aids. 2006;20(9):1295–302.
37. Safren S, O’Cleirigh C, Bullis J, Otto M, Stein M, Pollack M. An introduction to delivering cognitive behavioral therapy for adherence and depression (CBT-AD) for individuals living with HIV infection. 5th International conference on HIV treatment adherence. Miami; 2010.
38. Safren SA, O’Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80(3):404–15.
39. Tetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA. Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. J Addict Med. 2013;7(2):102–7.
40. Sobel LC, Sobel MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Allen JP, Litten RZ, editors. Measuring alcohol consumption: psychosocial and biochemical methods. Totowa: Human Press; 1992. p. 41–72.
41. Litman GK, Stapleton J, Oppenheim AN, Peleg M, Jackson P. Relationship between coping behaviors, their effectiveness and alcoholism relapse and survival. Br J Addict. 1984;79:283–91.
42. Lamb RJ, Kirby KC, Morral AR, Galbicka G, Iguchi MY. Improving contingency management programs for addiction. Addict Behav. 2004;29(3):507–23.
43. Herbert JD, Goetter EM, Forman EM, Yuen EK, Erford BM, Milillo JJ, et al. Crossing the line: interstate delivery of remote psychological services. Behav Ther. 2012;35:145–52.
44. Liu H, Miller LG, Golin CE, Hays RD, Wu T, Wenger NS, et al. Repeated measures analyses of dose timing of antiretroviral medication and its relationship to HIV virologic outcomes. Stat Med. 2007;26(5):991–1007.
45. Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41(3):315–22.